Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 1041Cyclophosphamide 974Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 760Paclitaxel 740Docetaxel 734Oxaliplatin 706Capecitabine 650Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 327Trastuzumab 324Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 279Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × TLC 388 × Clear all
NCT02457273 2019-04-03

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

National Health Research Institutes, Taiwan

Phase 2 Completed
23 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡